Conditions: Open-angle Glaucoma Ocular Hypertension
Keywords: Glaucoma Open-angle glaucoma Ocular hypertension Hypertension Eye Diseases Vascular Diseases Cardiovascular Diseases Travoprost Antihypertensive Agents Cardiovascular Agents Therapeutic Uses Pharmacologic Actions
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 191
Healthy volunteers: no

Brief summary:
The purpose of this study was to assess the efficacy and tolerability of TRAVATAN® solution without BAK (benzalkonium chloride) after changing from prior latanoprost 0.005% ophthalmic solution monotherapy in subjects with open-angle glaucoma or ocular hypertension due to tolerability issues.

Detailed description:

Arms:
arm 1: Travoprost 0.004% BAK-free, 1 drop self-administered to the study eye(s) once daily, every evening at around 8:00 pm, for 12 weeks.

Interventions: intervention 1: Travoprost 0.004% BAK-free
Intervention descriptions: intervention 1: Containing Polyquad (PQ) preservative

Protocol document: